Design Review,Video capsule endoscopy (VCE

The use of semaglutide, a popular GLP-1 receptor agonist widely prescribed for diabetes and weight loss, has raised important considerations for patients undergoing capsule endoscopy. This diagnostic procedure, which involves swallowing a tiny capsule with a camera inside to visualize the gastrointestinal tract, is crucial for assessing various conditions. However, emerging research indicates that semaglutide use can increase residual gastric content, potentially affecting the accuracy and safety of endoscopic examinations.

Recent studies, including those cited by GH Gu and H Korlipara, have highlighted a significant association between semaglutide and retained gastric contents during endoscopic procedures. This means that patients taking semaglutide may have more undigested food or fluid in their stomach when the procedure begins. This phenomenon is not unique to capsule endoscopy; it has also been observed in other endoscopic procedures like EGD (esophagogastroduodenoscopy). The implications of this are substantial, as a clear view of the gastrointestinal lining is essential for accurate diagnosis.

One of the primary mechanisms behind this effect is the known impact of GLP-1 receptor agonists on gastrointestinal motility. Research indicates that GLP-1 RAs affect transit time in patients with diabetes and can prolong gastric transit time (GTT). For instance, a study by J Crespo found that the median gastric transit time (GTT) increases from 34 to 78 min in patients on weekly semaglutide. This delay in gastric emptying means that the capsule endoscopy camera may encounter more residual material, potentially obscuring the view of the small intestine. A study by T Odah further supports this, noting that Video capsule endoscopy (VCE) is valuable for assessing conditions like GI bleeding, anemia, and inflammatory bowel disease, but GLP-1 receptor agonists can influence its effectiveness.

The consequence of increased residual gastric content during capsule endoscopy can lead to a higher incidence of incomplete examinations. A study by T Odah reported that a notable percentage of patients on GLP-1 RAs experienced incomplete passage of the videocapsule endoscopy through the small intestine. This necessitates repeat procedures, leading to increased costs, patient inconvenience, and potential delays in diagnosis.

Given these findings, medical professionals are increasingly considering the need to hold the GLP-1 medication before elective capsule endoscopy. While the American Gastroenterological Association (AGA) currently doesn't endorse all patients stopping GLP-1 RAs prior to elective endoscopic procedures, individual risk assessment is paramount. Recommendations vary, but some guidelines suggest patients should stop 1 week before the procedure when taking medications like semaglutide (brand names include Ozempic, Rybelsus, and Wegovy), dulaglutide (Trulicity), and liraglutide. This proactive approach aims to minimize the risk of pulmonary aspiration of gastric contents, a serious concern, especially in patients undergoing procedures that might involve sedation.

The impact of semaglutide on the effectiveness of capsule endoscopy is an area of ongoing research. While semaglutide can offer significant benefits for managing diabetes and obesity, its influence on gastrointestinal transit time is a crucial factor to consider before undergoing diagnostic procedures. The ability of semaglutide to potentially enhance the results of endoscopy for obesity is an intriguing prospect, but ensuring the procedural integrity of capsule endoscopy remains a priority.

In summary, patients prescribed semaglutide or other GLP-1 receptor agonists should have a detailed discussion with their healthcare provider regarding their upcoming capsule endoscopy. Understanding the potential for increased residual gastric content and prolonged gastric transit time is essential for optimizing the diagnostic yield of this important endoscopic tool. This includes considering appropriate medication management, such as temporary discontinuation of the drug, to ensure the most accurate and safe endoscopic exam of the small intestine.